156 related articles for article (PubMed ID: 36755439)
41. Pharmacogenomics: An evolving clinical tool for precision medicine.
Hockings JK; Pasternak AL; Erwin AL; Mason NT; Eng C; Hicks JK
Cleve Clin J Med; 2020 Feb; 87(2):91-99. PubMed ID: 32015062
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Fragoulakis V; Bartsakoulia M; Díaz-Villamarín X; Chalikiopoulou K; Kehagia K; Ramos JGS; Martínez-González LJ; Gkotsi M; Katrali E; Skoufas E; Vozikis A; John A; Ali BR; Wordsworth S; Dávila-Fajardo CL; Katsila T; Patrinos GP; Mitropoulou C
Pharmacogenomics J; 2019 Oct; 19(5):438-445. PubMed ID: 30647444
[TBL] [Abstract][Full Text] [Related]
43. Pharmacogenetics of cutaneous adverse drug reactions.
Aihara M
J Dermatol; 2011 Mar; 38(3):246-54. PubMed ID: 21342226
[TBL] [Abstract][Full Text] [Related]
44. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
45. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
McGrane IR; Loveland JG
J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
[TBL] [Abstract][Full Text] [Related]
47. Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping.
Liu J; Xu Z; Li Y; Dai S; Liu J; Pan J; Jiang Y
Mol Membr Biol; 2019 Dec; 35(1):1-8. PubMed ID: 30916611
[TBL] [Abstract][Full Text] [Related]
48. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Biswas M; Rahaman S; Biswas TK; Ibrahim B
Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763
[TBL] [Abstract][Full Text] [Related]
49. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Wang T; Li H; Wang F; Sun L; Yu L
Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
[TBL] [Abstract][Full Text] [Related]
50. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
Yampayon K; Sukasem C; Limwongse C; Chinvarun Y; Tempark T; Rerkpattanapipat T; Kijsanayotin P
Eur J Clin Pharmacol; 2017 Jul; 73(7):855-865. PubMed ID: 28391407
[TBL] [Abstract][Full Text] [Related]
51. CYP2C19 and CYP2D6 genotypes in Pacific peoples.
Helsby NA
Br J Clin Pharmacol; 2016 Nov; 82(5):1303-1307. PubMed ID: 27304207
[TBL] [Abstract][Full Text] [Related]
52. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
53. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians.
Park MW; Her SH; Kim CJ; SunCho J; Park GM; Kim TS; Choi YS; Park CS; Koh YS; Park HJ; Kim PJ; Chung WS; Seung KB; Kim HS; Shin JG; Chang K
Genet Med; 2016 Aug; 18(8):833-41. PubMed ID: 26699760
[TBL] [Abstract][Full Text] [Related]
55. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
[TBL] [Abstract][Full Text] [Related]
56. Genotyping
Jantararoungtong T; Tempark T; Koomdee N; Medhasi S; Sukasem C
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1049-1064. PubMed ID: 34148467
[No Abstract] [Full Text] [Related]
57.
Satapornpong P; Pratoomwun J; Rerknimitr P; Klaewsongkram J; Nakkam N; Rungrotmongkol T; Konyoung P; Saksit N; Mahakkanukrauh A; Amornpinyo W; Khunarkornsiri U; Tempark T; Wantavornprasert K; Jinda P; Koomdee N; Jantararoungtong T; Rerkpattanapipat T; Wang CW; Naisbitt D; Tassaneeyakul W; Ariyachaipanich M; Roonghiranwat T; Pirmohamed M; Chung WH; Sukasem C
Front Immunol; 2021; 12():661135. PubMed ID: 34017337
[No Abstract] [Full Text] [Related]
58. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
[TBL] [Abstract][Full Text] [Related]
59. Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine.
Biswas M; Shobana J; Jinda P; Sukasem C
Expert Opin Drug Metab Toxicol; 2023 Mar; 19(3):165-174. PubMed ID: 37089014
[TBL] [Abstract][Full Text] [Related]
60. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
